DIGITAL DOSE INHALER MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Digital Dose Inhaler Market Size and Trends

Global digital dose inhaler market is estimated to be valued at USD 18.33 Bn in 2024 and is expected to reach USD 64.33 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 19.6% from 2024 to 2031.

To learn more about this report, request sample copy

Global digital dose inhaler market is expected to witness significant growth over the forecast period due to rising prevalence of respiratory diseases worldwide and increasing adoption of digital healthcare. Advanced features of digital dose inhalers such as dose counters, humidity controls and integrated sensors are enhancing patient compliance. Moreover, integration of these devices with mobile applications is enabling remote monitoring of patients, thereby, improving health outcomes. Telehealth and remote monitoring are expected to contribute gains in the digital dose inhaler market over the next few years. However, lack of awareness regarding digital dose inhalers and their high costs may hamper the market growth over the forecast period.

Rising Prevalence of Respiratory Diseases

Growing prevalence of respiratory diseases like asthma and COPD across the globe is a major factor boosting demand for digital dose inhalers. Respiratory diseases have become one of the top causes of death and disability globally. According to the estimates, over 334 million people are suffering from asthma globally and 250,000 deaths are attributed to the disease each year. The condition is more prevalent among children as compared to adults. Growing environmental pollution levels and changes in lifestyle habits have contributed significantly to rising cases of asthma in both developing and developed nations. Respiratory infections are ranked as the greatest single contributor to the overall burden of disease in the world. According to the World Health Organization Data in May 2023, approximately 262 million individuals are estimated to be afflicted by asthma. As the number of people battling these chronic respiratory illnesses increases, it boosts sales of digitally operated inhalers which helps to effectively manage symptoms and ensure medication adherence.

Increasing adoption of organic growth strategies such as product launch by key market players is expected to drive the growth of digital dose inhaler market over the forecast period. For instance, in September 2020, Teva Pharmaceutical Industries Ltd., a pharmaceutical company, announced the launch of AirDuo Digihaler (fluticasone propionate and salmeterol) inhalation powder and ArmonAir Digihaler (fluticasone propionate) inhalation powder, two digital maintenance inhalers for patients with asthma. AirDuo Digihaler is a prescription medicine that is used to control symptoms of asthma and prevent symptoms such as wheezing in people 12 years of age and older. ArmonAir Digihaler is a prescription medicine for the long-term treatment of asthma in patients 12 years and older.